Novel Antibody Therapy Market By Type (Monoclonal antibodies (mAbs), Antibody-drug conjugates (ADCs), Bispecific antibodies (BsAbs), Others), Therapeutic Area (Oncology, Autoimmune diseases, Infectious diseases, Others), End-User (Hospitals, Specialty centers, Others), and Region - Partner & Customer Ecosystem (Product Services, Proposition & Key Features) Competitive Index & Regional Footprints by MarketDigits - Forecast 2024-2032

Industry : Healthcare | Pages : 191 Pages | Published On : Apr 2024

         
     
The Novel Antibody Therapy Market is Valued USD 2.4 billion by 2024 and projected to reach USD 12.08 billion by 2032, growing at a CAGR of 19.7% During the Forecast period of 2024-2032.

Novel Antibody Therapy Market Size


Graph
             2020                         2024-2032      

ReportDetails
Market Size ValueUSD 2.4 billion by 2024
Market Size ValueUSD 12.08 billion by 2032
CAGR19.7%
Forecast Period2024-2032
Base Year 2023
Historic Data2020
Forecast UnitsValue (USD Million/USD Billion)
Segments CoveredType, Therapeutic Area, End User and Region
Geographics CoveredNorth America, Europe, Asia Pacific, and RoW

Major vendors in the global Novel Antibody Therapy Market: Actinium Pharmaceuticals, Molecular Templates, Philogen, Roche, Seagen, Sesen bio, Telix Pharmaceuticals, Y-mAbs Therapeutics, AstraZeneca Plc., Bristol-Myers Squibb Co., Eli Lilly and Company and Others

Market Overview

The Novel Antibody Therapy Market is a dynamic and rapidly evolving sector characterized by a diverse range of therapies designed to harness the specificity of antibodies for therapeutic purposes. Antibody therapies, particularly monoclonal antibodies (mAbs), have gained prominence across various therapeutic areas, including oncology, autoimmune diseases, and infectious diseases. These therapies leverage different mechanisms of action, such as immune checkpoint inhibition, antibody-drug conjugates (ADCs), and bispecific antibodies, offering targeted and personalized treatment approaches. With ongoing advancements in research and development, the market showcases a continuum of products at various stages, from early-phase investigational therapies to commercially available products. Key factors driving market growth include the expanding understanding of disease biology, increased investment in biopharmaceutical research, and the successful translation of scientific discoveries into clinically effective antibody-based treatments. The market segmentation encompasses factors such as the type of antibody, therapeutic area, mechanism of action, target antigen, mode of administration, end-users, geography, and development stage, reflecting the complexity and diversity within this burgeoning field

Rising prevalence of chronic and infectious diseases

The rising prevalence of chronic and infectious diseases worldwide serves as a key driver for the Novel Antibody Therapy Market. As the global burden of diseases such as cancer, autoimmune disorders, and infectious diseases continues to grow, there is an escalating demand for targeted and effective therapeutic interventions. Antibody therapies, particularly monoclonal antibodies, have emerged as versatile tools in addressing these health challenges. Their ability to selectively target specific disease-related antigens, modulate immune responses, and deliver cytotoxic payloads positions them as valuable candidates for treating a wide range of conditions. The precision and specificity offered by novel antibody therapies make them promising options for improving patient outcomes and quality of life, thus driving the growth of the market in response to the increasing healthcare needs associated with chronic and infectious diseases worldwide.

Market Dynamics

Drivers:

  • Booming biologics industry
  • Rising applications of antibody therapy
  • Growing research and development activities

Opportunities:

  • Expansion into new therapeutic areas
  • Development of personalized and precision medicine approaches
  • Development of combination therapies

Emergence of Antibody-Drug Conjugates (ADCs)

The emergence of Antibody-Drug Conjugates (ADCs) represents a significant trend in the Novel Antibody Therapy Market. ADCs are a class of innovative biopharmaceuticals that combine the specificity of monoclonal antibodies with the cytotoxic potency of small-molecule drugs. This trend is driven by the desire to enhance the precision and efficacy of cancer treatment. ADCs are designed to selectively deliver cytotoxic payloads directly to cancer cells, minimizing damage to healthy tissues and reducing systemic side effects. The approach holds promise for targeted therapy in oncology, addressing challenges associated with traditional chemotherapy. As ADCs progress through clinical trials and gain regulatory approvals, they exemplify a transformative trend in the development of novel antibody therapies, offering new possibilities for more effective and personalized cancer treatments.

The market for Novel Antibody Therapy Market is dominated by North America.

North America dominated the novel antibody therapy market. This is due to a number of factors, including the strong presence of large pharmaceutical and biotechnology companies in the region, the high prevalence of chronic and infectious diseases, and the supportive regulatory environment. The U.S. is the largest market for novel antibody therapies in North America, followed by Canada. The U.S. market is benefiting from the FDA's expedited review program for breakthrough therapies, which has helped to accelerate the approval of new antibody therapies. The Canadian market is also growing, thanks to the increasing adoption of novel antibody therapies by hospitals and specialty centers.

The Asia-Pacific region is the fastest-growing region for the novel antibody therapy market. The Asia-Pacific region has the world's largest population and the highest prevalence of chronic and infectious diseases. This is creating a significant demand for effective and targeted therapies. Disposable incomes in the Asia-Pacific region are rising, which is increasing the demand for healthcare services, including novel antibody therapies. The healthcare infrastructure in the Asia-Pacific region is expanding rapidly, which is making novel antibody therapies more accessible to patients. The number of clinical trials for novel antibody therapies in the Asia-Pacific region is increasing, which is helping to accelerate the development and approval of new therapies.

Monoclonal antibodies (mAbs) Segment is Anticipated to Hold the Largest Market Share During the Forecast Period

Based on by type the Novel antibody therapy market is categorized into Monoclonal antibodies (mAbs), Antibody-drug conjugates (ADCs), Bispecific antibodies (BsAbs), Others.  Monoclonal antibodies (mAbs) held the largest share of the novel antibody therapy market in 2021, accounting for approximately 70% of the global market share. This dominance is attributed to several factors, including their high specificity, ability to target specific antigens, and diverse range of applications. mAbs offer a precise and targeted approach to treatment, minimizing the impact on healthy cells and enhancing treatment efficacy. Their versatility has led to their utilization in treating a wide spectrum of diseases, including cancer, autoimmune disorders, and infectious diseases. The ability to tailor mAb therapies to individual patient profiles further contributes to their widespread adoption.

Major Segmentations Are Distributed as follows:

  • By Type
    • Monoclonal antibodies (mAbs)
    • Antibody-drug conjugates (ADCs)
    • Bispecific antibodies (BsAbs)
    • Others
  • By Therapeutic Area
    • Oncology
    • Autoimmune diseases
    • Infectious diseases
    • Others
  • By End-User
    • Hospitals
    • Specialty centers
    • Others
  • By Region
    • North America
      • US
      • Canada
    • Latin America
      • Brazil
      • Mexico
      • Argentina
      • Colombia
      • Chile
      • Peru
      • Rest of Latin America
    • Europe
      • Germany
      • France
      • Italy
      • Spain
      • U.K.
      • BENELUX
      • CIS & Russia
      • Nordics
      • Austria
      • Poland
      • Rest of Europe
    • Asia Pacific
      • China
      • Japan
      • South Korea
      • India
      • Thailand
      • Indonesia
      • Malaysia
      • Vietnam
      • Australia & New Zealand
      • Rest of Asia Pacific
    • Middle East & Africa
      • Saudi Arabia
      • UAE
      • South Africa
      • Nigeria
      • Egypt
      • Israel
      • Turkey
      • Rest of MEA

Answers to Following Key Questions:

  • What will be the Novel Antibody Therapy Market’s Trends & growth rate? What analysis has been done of the prices, sales, and volume of the top producers of Novel Antibody Therapy Market?
  • What are the main forces behind worldwide Novel Antibody Therapy Market? Which companies dominate Novel Antibody Therapy Market?
  • Which companies dominate Novel Antibody Therapy Market? Which business possibilities, dangers, and tactics did they embrace in the market?
  • What are the global Novel Antibody Therapy industry's suppliers' opportunities and dangers in Novel Antibody Therapy Market?
  • What is the Novel Antibody Therapy industry's regional sales, income, and pricing analysis? In the Novel Antibody Therapy Market, who are the distributors, traders, and resellers?
  • What are the main geographic areas for various trades that are anticipated to have astounding expansion over the Novel Antibody Therapy Market?
  • What are the main geographical areas for various industries that are anticipated to observe astounding expansion for Novel Antibody Therapy Market?
  • What are the dominant revenue-generating regions for Novel Antibody Therapy Market, as well as regional growth trends?
  • By the end of the forecast period, what will the market size and growth rate be?
  • What are the main Novel Antibody Therapy Market trends that are influencing the market's expansion?
  • Which key product categories dominate Novel Antibody Therapy Market? What is Novel Antibody Therapy Market’s main applications?
  • In the coming years, which Novel Antibody Therapy Market technology will dominate the market?

Reason to purchase this Novel Antibody Therapy Market Report:

  • Determine prospective investment areas based on a detailed trend analysis of the global Novel Antibody Therapy Market over the next years.
  • Gain an in-depth understanding of the underlying factors driving demand for different Novel Antibody Therapy Market segments in the top spending countries across the world and identify the opportunities each offers.
  • Strengthen your understanding of the market in terms of demand drivers, industry trends, and the latest technological developments, among others.
  • Identify the major channels that are driving the global Novel Antibody Therapy Market , providing a clear picture of future opportunities that can be tapped, resulting in revenue expansion.
  • Channelize resources by focusing on the ongoing programs that are being undertaken by the different countries within the global Novel Antibody Therapy Market.
  • Make correct business decisions based on a thorough analysis of the total competitive landscape of the sector with detailed profiles of the top Novel Antibody Therapy Market  providers worldwide, including information about their products, alliances, recent contract wins, and financial analysis wherever available.

TOC

Table and Figures

Methodology:

At MarketDigits, we take immense pride in our 360° Research Methodology, which serves as the cornerstone of our research process. It represents a rigorous and comprehensive approach that goes beyond traditional methods to provide a holistic understanding of industry dynamics.

This methodology is built upon the integration of all seven research methodologies developed by MarketDigits, a renowned global research and consulting firm. By leveraging the collective strength of these methodologies, we are able to deliver a 360° view of the challenges, trends, and issues impacting your industry.

The first step of our 360° Research Methodology™ involves conducting extensive primary research, which involves gathering first-hand information through interviews, surveys, and interactions with industry experts, key stakeholders, and market participants. This approach enables us to gather valuable insights and perspectives directly from the source.

Secondary research is another crucial component of our methodology. It involves a deep dive into various data sources, including industry reports, market databases, scholarly articles, and regulatory documents. This helps us gather a wide range of information, validate findings, and provide a comprehensive understanding of the industry landscape.

Furthermore, our methodology incorporates technology-based research techniques, such as data mining, text analytics, and predictive modelling, to uncover hidden patterns, correlations, and trends within the data. This data-driven approach enhances the accuracy and reliability of our analysis, enabling us to make informed and actionable recommendations.

In addition, our analysts bring their industry expertise and domain knowledge to bear on the research process. Their deep understanding of market dynamics, emerging trends, and future prospects allows for insightful interpretation of the data and identification of strategic opportunities.

To ensure the highest level of quality and reliability, our research process undergoes rigorous validation and verification. This includes cross-referencing and triangulation of data from multiple sources, as well as peer reviews and expert consultations.

The result of our 360° Research Methodology is a comprehensive and robust research report that empowers you to make well-informed business decisions. It provides a panoramic view of the industry landscape, helping you navigate challenges, seize opportunities, and stay ahead of the competition.

In summary, our 360° Research Methodology is designed to provide you with a deep understanding of your industry by integrating various research techniques, industry expertise, and data-driven analysis. It ensures that every business decision you make is based on a well-triangulated and comprehensive research experience.

Novel Antibody Therapy Market
Customize your Report
• Tailored advice to Drive your Performance
• Product Planning Strategy
• New Product Stratergy
• Expanded Research Scope
• Comprehensive Research
• Strategic Consulting
• Provocative and pragmatic
• Accelerate Revenue & Growth
• Evaluate the competitive landscape
• Optimize your partner network
• Analyzing industries
• Mapping trends
• Strategizing growth
• Implementing plans
A comprehensive cogent custom study with Analyzing Industries, Mapping Trends, Straterging growth & Implementing Plans. An in-depth and breadth of composite research, which gives complete support of the generation and evaluation of growth opportunities, and best practices recognition to help increase the revenue. Request a Custom Research below.
Request Customization

Covered Key Topics

Growth Opportunities

Market Growth Drivers

Leading Market Players

Company Market Share

Market Size and Growth Rate

Market Trend and Technological

Research Assistance

We will be happy to help you find what you need. Please call us or write to us:

+1 510-730-3200 (USA Number)

Email: sales@marketdigits.com